Declarations Authors contributions Designed the paper, selected and prepared the references, prepared the figures, wrote the manuscript: Wright JW Prepared the references, wrote the manuscript: Harding JW Availability of data and materials Not applicable
GSDMD deficiency inhibits the expression and secretion level of CCL11 in vivo and in vitro In vitro observations verified that endothelial function and tube formation were exacerbated by the culture supernatants of GSDMD-KD macrophages
Trials investigating newer potential anti-obesity medications, including co-agonists and tri-agonists that target peptides such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), amylin, and glucagon are underway
Purified water, glyceret-26, methylpropanediol, butylene glycol, glycerin, 1,2-hexanediol, niacinamide, neopentyl glycol diheptanoate, polyglyceryl-3methyldistearate glucose, PEG-240/HDI copolymer bis-decyltetradecet-20 ester, caprylic acid triglyceride, phenyltrimethicone, glyceryl stearate, cyclopentasiloxane, PEG-60 hydrogenated castor oil, cyclohexasiloxane, acryloyldimethyl ammonium taurate/Vpicopolymer, C12-16 alcohol, glutathione (990 ppm), palmitic acid, hydrogenated lecithin, ethylhexylglycerin, adenosine, persimmon extract, chloramine T, sodium bicarbonate, sodium carbonate, propanediol, sodium hyaluronate crosslinking polymer (50 parts per million), lamium extract, bladderwrack extract, hydrolyzed glycosaminoglycan (30 parts per million), glycine, sodium hyaluronate (15 parts per million), serine, glutamic acid, potassium laurate, benzyl glycol, asparagic acid, leucine, BHT, alanine, lysine, arginine, tyrosine, phenylalanine, threonine, proline, valine, isoleucine, hydrolyzed hyaluronic acid (2
